Drug intelligence / Profile preview

MBTC-ALS-EVs

Development stage: Preclinical
Lead developer: Stemmedicare
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

MBTC-ALS-EVs is an extracellular vesicle (EV)-based therapeutic candidate being developed by Stemmedicare for the treatment of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease. The drug leverages Stemmedicare's proprietary immune-tolerized EV platform to deliver therapeutic biological factors. While specific molecular targets have not been publicly disclosed, the therapy is designed to utilize the neuroprotective and regenerative potential of stem cell-derived EVs to slow or halt the progression of neurodegeneration in ALS patients. It is currently in the preclinical stage of development, specifically undergoing efficacy verification.

Beyond the preview

Go deeper on MBTC-ALS-EVs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBTC-ALS-EVs.

Explore the full profile